11 October 2018
–
Mithra (Euronext Brussels: MITRA), a Liège-based company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference held yesterday. News was very positive, with the company reporting strong clinical and financial results.
2018 UPDATE AND 2019 OUTLOOK GIVEN AT THE CPHI CONFERENCE:
- Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for US market
- Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions
- Further Marketing authorisations obtained for MyRing™
- Continuously improved IP portfolio
- Strenghtened cash position
Read the full press release here.
